ABT
Updated: 24/09/2026, 05:41:34
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
No summaries found.
Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.
Revenue
$44.3B
FY 2025 · Reported
Net income
$6.5B
FY 2025 · Reported
Gross margin
56.4%
FY 2025 · Calculated
Free cash flow
$7.4B
FY 2025 · Calculated
R&D intensity
6.6%
FY 2025 · Calculated
Share repurchases
$0.9B
FY 2025 · Reported
Other offerings mentioned without separate sales
Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.
Map layer
Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.
Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.
Abbott overview
Illinois corporation (1900); broad diversified line of healthcare products
“Abbott’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products.”
Principal business
Abbott's principal business is the discovery, development, manufacture, and sale of a broad line of healthcare products.
“Abbott’s principal business is the discovery, development, manufacture, and sale of a broad line of healthcare products.”
Core product lines
Revenues from medical devices, diagnostics, nutrition, and branded generic pharmaceuticals; international markets are 61% of consolidated net sales
“Abbott’s revenues are derived primarily from the sale of a broad line of healthcare products, which include medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals”
Four reportable segments
Established Pharmaceutical Products; Diagnostic Products; Nutritional Products; Medical Devices
“Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.”
Medical Devices segment performance
Medical Devices sales +11.9% ex-FX in 2025; operating margin rose to 33.7%; double-digit growth in Diabetes Care, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management
“sales in the Medical Devices segment, excluding the impact of foreign exchange, increased 11.9 percent in 2025 and 13.7 percent in 2024”
Diagnostics segment headwinds
Diagnostics sales -4.5% ex-FX in 2025 on lower COVID testing and China volume-based procurement; margin fell to 19.5%; partially offset by Alinity rollout
“The 2025 and 2024 sales decreases were driven by continued lower demand for the company's portfolio of COVID-19 tests and challenging market conditions in China, including the impact of volume-based procurement programs.”
Nutritional Products segment performance
Nutrition: pediatric -0.7% ex-FX in 2025 (lower U.S. volumes), adult +2.7%; operating margin improved to 18.4%
“total pediatric nutrition sales, excluding the impact of foreign exchange, decreased 0.7 percent in 2025, reflecting lower sales volumes in the U.S.”
Established Pharmaceutical Products performance
EPD sales +7.4% ex-FX in 2025, broad-based across countries, led by cardiometabolic, gastroenterology, CNS/pain
“In Abbott's Established Pharmaceutical Products segment, excluding the impact of foreign exchange, sales increased 7.4 percent in 2025 and 9.2 percent in 2024.”
Established Pharmaceuticals R&D process
EPD does not actively pursue primary research; process spans 1 year (bioequivalence) to 6+ years (complex formulations)
“As Established Pharmaceutical Products does not actively pursue primary research, development usually begins with work on existing products or after the completion of an acquisition or licensing agreement.”
EPP customer channels
Sells to wholesalers, distributors, government agencies, healthcare facilities, pharmacies; government agencies important customers
“Government agencies are also important customers.”
Medical Devices portfolio
Cardiovascular devices, diabetes care/CGM (FreeStyle Libre), and neuromodulation devices
“a broad line of rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring (CGM) products”
Established Pharmaceutical Products portfolio
Branded generic pharmaceuticals sold outside the US in emerging markets across six therapeutic areas
“a broad line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets”
Diagnostic Products portfolio
Core lab, molecular, point-of-care, rapid, and informatics diagnostic systems sold worldwide
“a broad line of diagnostic systems and tests manufactured, marketed, and sold worldwide”
Nutritional Products portfolio
Pediatric and adult nutritional products including Similac, Ensure, Glucerna, PediaSure
“a broad line of pediatric and adult nutritional products manufactured, marketed, and sold worldwide”
Key 2025 medical device approvals
2025 approvals: Volt PFA (FDA+CE), Tendyne TMVR (FDA), TriClip (Japan), TactiFlex Duo (CE), Navitor TAVI expanded indication (CE)
“U.S. Food and Drug Administration (FDA) approval and CE Mark for the Volt™ Pulsed Field Ablation (PFA) System to treat patients with atrial fibrillation”
International and emerging markets share
International = 61% of consolidated net sales; emerging markets = 37% of sales, +5.1% in 2025 ex-FX
“Sales in international markets comprise 61 percent of consolidated net sales.”
Foreign currency translation loss exposure
Cumulative FX translation loss $(5,931)M at year-end 2025; $1,574M translation gain in 2025 OCI
“Cumulative foreign currency translation (loss) adjustments$(5,931)$(7,505)$(6,504)”
Exact Sciences acquisition agreement
Definitive agreement (Nov 19, 2025) to acquire Exact Sciences to enter cancer diagnostics market
“On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation (Exact Sciences), which is expected to enable Abbott to enter the cancer diagnostics market.”
Pending acquisition of Exact Sciences
Agreement (Nov 19, 2025) to acquire Exact Sciences at $105/share cash; ~$21B equity value, ~$23B enterprise value, absorbing ~$1.8B net debt; enables entry into cancer diagnostics
“Under the terms of the agreement, Abbott will pay $105 per common share in cash at the completion of the transaction, representing a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion.”
Acquisitions of businesses
Acquisitions of businesses and technologies, net of cash acquired: $105M (2025), $877M (2023)
“Acquisitions of businesses and technologies, net of cash acquired(105)— (877)”
Capital expenditures
Acquisitions of property and equipment: $2,171M (2025), $2,207M (2024), $2,202M (2023)
“Acquisitions of property and equipment(2,171)(2,207)(2,202)”
Research and development spending
R&D expense: $2,942M (2025), $2,844M (2024), $2,741M (2023)
“Research and development2,942 2,844 2,741”
Established Pharmaceuticals R&D focus
Expand emerging-markets portfolios and biosimilars; develop key brands Creon™, Duphaston™, Femoston™, Influvac™
“Abbott plans to expand its product portfolio in key therapeutic areas and biosimilars ... Abbott is also actively working on the further development of several key brands such as Creon™, Duphaston™, Femoston™, and Influvac™.”
Nutritionals R&D focus
Pediatric and adult nutrition platforms: GI/immunity, brain health, mobility and metabolism, user experience
“Abbott is focusing its research and development spend on platforms that span the pediatric and adult nutrition areas: gastrointestinal/immunity health, brain health, mobility and metabolism, and user experience platforms.”
Diagnostics R&D focus
Blood/plasma screening, Core Lab systems, assay pipelines, informatics/automation, and rapid diagnostics
“Abbott continues to develop and commercialize next-generation blood and plasma screening systems and assays, as well as Core Laboratory immunoassay, clinical chemistry and hematology diagnostic systems and assays.”
Medical Devices R&D focus areas
Seven device R&D areas: CRM, Heart Failure, Electrophysiology, Vascular, Structural Heart, Neuromodulation, Diabetes Care
“Cardiac Rhythm Management – Development of next-generation rhythm management technologies, including advanced communication capabilities and leadless pacing therapies.”
Bridge facility for Exact Sciences acquisition
Commitment for a 364-day senior unsecured bridge term loan of up to $20.0 billion as back-up financing for the Exact Sciences acquisition
“Abbott obtained a commitment for a 364-day senior unsecured bridge term loan facility for an amount not to exceed $20.0 billion in conjunction with its pending acquisition of Exact Sciences.”
Debt structure and repayment activity
Long-term debt reduced to $9,896M (2024: $12,625M); current portion $3,033M; $1,504M repaid in 2025; interest expense $493M
“Repayments of long-term debt and debt with maturities over 3 months(1,504)(660)(2,498)”
2026 strategic priorities
2026 focus: Alinity/menus and digital health in diagnostics; newly launched device growth; nutrition new products; EPD emerging markets and biosimilars
“In 2026, Abbott will continue to invest in product development areas that provide the opportunity for strong sustainable growth over the next several years.”
No individual R&D project material
No individual project expected to be material over next five years; no material 2025 R&D delays
“no individual project is expected to be material to cash flows or results of operations over the next five years ... There were no delays in Abbott's 2025 research and development activities that are expected to have a material impact on operations.”
Dividends and buybacks
Dividends paid $4,116M in 2025 (per share $2.40 vs $2.24 in 2024, $2.08 in 2023); share repurchases $893M
“Dividends paid(4,116)(3,836)(3,556)”
Goodwill and intangibles balance
Goodwill $24,035M; net intangibles $5,526M (down from $6,647M) at year-end 2025
“Intangible assets, net of amortization5,526 6,647 Goodwill24,035 23,108”
FDA and international regulatory compliance cost
Products rigorously regulated by FDA and numerous international authorities; compliance costly
“Abbott’s products are subject to rigorous regulation by the FDA and numerous international, supranational, federal, and state authorities.”
EU MDR transition timeline
EU MDR applies as of May 26, 2021 with extended transition periods lasting as long as December 31, 2028
“The MDR applies to manufacturers as of May 26, 2021, with extended transition periods lasting as long as December 31, 2028, depending on the risk classification of the device in the regulation.”
EU IVDR transition timeline
IVDR took effect May 26, 2022; amended July 2024 to extend transition dates up to December 2029
“In July 2024, the IVDR was amended to extend the transition timeline period for dates of compliance as long as December 2029, depending on the diagnostic device classification.”
Infant formula FDA notification requirement
FDA notification and no-objection confirmation required before launch of infant formula or packaging changes
“Prior to the launch of an infant formula or product packaging change, the company is required to obtain the FDA's confirmation that it has no objections to the proposed product or packaging.”
US FDA device classifications
Most devices follow 510(k) or PMA pathways; most diagnostics are Class I/II
“Most of Abbott's medical device products are classified as Class II devices that follow the 510(k) regulatory process or Class III devices that are subject to the PMA process.”
Supply chain disruption risk
Global supply chain disruptions could negatively affect results; prior COVID/inflation/labor-shortage impacts
“the COVID-19 pandemic and macroeconomic conditions such as inflationary pressures and labor shortages contributed to global supply chain challenges”
Cybersecurity and data privacy risk
Significant cybersecurity incident or data breach could have material adverse effect
“A significant cybersecurity incident or other disruption affecting Abbott’s information systems or products could have a material adverse effect”
R&D and data-driven business model risk
R&D efforts and data-driven healthcare business models may not succeed, reducing revenue/profitability
“Abbott is developing new business and operating models necessary to support the creation of data-driven healthcare solutions”
Exact Sciences acquisition indebtedness
Abbott plans to fund Exact Sciences acquisition with ~$20 billion of borrowings; existing debt ~$12.9B
“Abbott plans to fund the Exact Sciences acquisition with approximately $20 billion of borrowings.”
Acquisition/disposition execution risk
M&A activity could increase costs, debt, and impair profitability
“Abbott may not be able to integrate acquisitions successfully into its existing business or transition disposed businesses efficiently, and could incur or assume significant debt and unknown or contingent liabilities.”
All four segments' products require FDA and international approvals and ongoing compliance including facility inspections.
“Abbott’s products are subject to rigorous regulation by the FDA and numerous international, supranational, federal, and state authorities.”
U.S. accounts for 39% of sales; lower U.S. volumes drove flat nutrition results and pediatric declines.
“Results in the Nutritional Products segment were flat, reflecting price increases and lower volumes, particularly in the United States (U.S.).”
Emerging markets are 37% of sales and a key growth engine (EPD strategy, nutrition growth).
“Sales in emerging markets, which represent 37 percent of total company sales, increased 5.1 percent in 2025”
Declining COVID-19 testing demand is a persistent headwind to Diagnostics sales and margins.
“Sales also continued to be affected by the decline in COVID‑19 testing‑related sales in the Diagnostics segment.”
Operations and products rely on complex information systems vulnerable to cyber incidents.
“the size and complexity of the information systems on which Abbott relies for both its infrastructure and products make them susceptible to a cybersecurity incident”
Foreign exchange translation affects sales measurement, margins, and goodwill/intangibles; cited as an offset in 2025 margin gains.
“the measurement of net sales and costs is impacted by foreign currency translation”
Global supply chain disruptions previously raised costs and reduced availability of raw materials and supplies.
“adversely impacted the cost and availability of certain raw materials, supplies, and services”
Foreign subsidiaries' earnings and net assets are translated into USD; large cumulative translation loss in AOCI shows significant non-USD asset exposure.
“The statements of earnings of foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using average exchange rates for the period.”
Alinity deployment and expanded test menus underpin Diagnostics growth strategy amid COVID declines.
“the continued deployment of Abbott's Alinity® testing platform and digital health solutions, as Abbott continues to expand its diagnostic test menus”
FDA classification pathways (510(k) for Class II, PMA for Class III, BLA for blood screening) govern Abbott's device and diagnostic approvals in the U.S.
“Class II products typically require premarket notification to the FDA through a regulatory filing known as a 510(k) submission. Most Class III products are subject to the FDA's Premarket Approval (PMA) requirements.”
Diagnostics revenue model bundles instruments, reagents, procedures, and service agreements as multiple performance obligations, indicating a recurring reagent/service revenue stream.
“Abbott participates in selling arrangements that include multiple performance obligations (e.g., instruments, reagents, procedures, and service agreements).”
Manufacturing and input cost inflation partially offset margin improvement and price increases.
“partially offset by continued inflation in manufacturing and input costs and the impact of foreign exchange”
China volume-based procurement programs pressured Diagnostics sales.
“challenging market conditions in China, including the impact of volume-based procurement programs”
$20B of new acquisition borrowings risk credit rating deterioration and higher borrowing costs.
“Adverse changes in Abbott's credit ratings may result in increased borrowing costs for future long-term debt or short-term borrowing facilities”
TCJA transition tax and GILTI shape Abbott's tax provision on foreign earnings.
“The TCJA subjects taxpayers to tax on global intangible low-taxed income (GILTI) earned by certain foreign subsidiaries.”
MDR imposes additional premarket and post-market requirements on Abbott's medical devices in the EU, with CE marking required and transitions up to December 31, 2028.
“the EU adopted the new Medical Devices Regulation (MDR) which replaced the existing directives in the EU for medical devices and imposes additional premarket and post-market regulatory requirements”
Proposed 15% global minimum tax could affect Abbott's international tax burden, though January 2026 guidance would exempt U.S.-parented groups when enacted.
“Pillar 2 proposes to assess a 15 percent minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis.”
Failure to develop data-driven healthcare business models may reduce demand for Abbott products.
“Failure to develop and maintain business and operating models necessary to support data-driven healthcare solutions may negatively impact the demand for Abbott products”
IVDR imposes additional premarket and post-market requirements on Abbott's diagnostics products in the EU, with transition dates up to December 2029.
“the EU adopted the new In Vitro Diagnostic Regulation (IVDR) which replaced the existing directive in the EU for in vitro diagnostic products and imposed additional premarket and post-market regulatory requirements”
See which prediction-market events move ABT, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Abbott (ABT) Stock Declines While Market Improves: Some Information for Investors
Zacks Investment Research • STOCK • 12/06/2026, 20:50:27
Abbott declares 410th consecutive quarterly dividend
PRNewsWire • STOCK • 12/06/2026, 16:29:00
Abbott Laboratories Remains Structurally Undervalued
Seeking Alpha • STOCK • 12/06/2026, 05:46:33
Abbott (ABT) Dips More Than Broader Market: What You Should Know
Zacks Investment Research • STOCK • 10/06/2026, 21:02:01
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Zacks Investment Research • STOCK • 10/06/2026, 12:01:27
New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
PRNewsWire • STOCK • 08/06/2026, 11:00:00
Baron Discovery Fund Q1 2026: Who Moved The Needle
Seeking Alpha • STOCK • 08/06/2026, 03:35:00
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
PRNewsWire • STOCK • 06/06/2026, 11:00:00
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Zacks Investment Research • STOCK • 29/05/2026, 12:01:18
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
Zacks Investment Research • STOCK • 28/05/2026, 12:31:17
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know
Zacks Investment Research • STOCK • 27/05/2026, 20:51:04
ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
PRNewsWire • STOCK • 27/05/2026, 09:01:00
